Pharmacokinetic model of R-roscovitine and its metabolite in health male subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 4, 2004, Pages 232-239

  de la Motte, S ^a,c   Gianella Borradori, A ^b  

^a Harrison Clinical Research GmbH   (Germany)

^b CYCLACEL LTD   (United Kingdom)

^c NONE   (Germany)

Author keywords

Compartment model; Healthy volunteers; Kinase inhibitor; Pharmacokinetics; R roscovitine

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DRUG METABOLITE; ROSCOVITINE; WATER;

ADULT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG ISOLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG URINE LEVEL; FIRST PASS EFFECT; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; SLOW RELEASE FORMULATION;

EID: 1842637406     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp42232     Document Type: Article

References (7)

1. Benson C, White J, Twelves C, O'Donnell A, Cruickshank C, Tan S, Gianella-Borradori A, Judson L 2003 A phase I trial of the oral cyclin-dependent kinase inhibitor CYC202 in patients with advanced malignancy. American Society of Clinical Oncology, Annual Meeting, Abstract No. 838, Chicago
2. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH 1996 Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6: 159-176
3. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP 2002 In vitro and in vivo antitumor properties of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102: 463-468
4. Raymond E, Laurence V, Faivre S, Vera K, Pierga JY, Delbaldo C, Bekradda M, Armand JP, Gianella-Borradori A, Dieras V 2002 Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies. Eur J Cancer 38 (Suppl 7): 49
5. Senn S 1993 Crossover trials in clinical research. Wiley and Sons, Chichester
6. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S 1992 Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 81: 309-312
7. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 2001 Guidance for industry: bioanalytical method validation. Drug Information Branch/Center for Drug Evaluation and Research, Rockville